Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mepivacaine hydrochloride + epinephrine is a combination pharmaceutical product used for local anesthesia, particularly in dental procedures. Mepivacaine is an amide-type local anesthetic that works by binding to and blocking voltage-gated sodium channels on the neuronal membrane, which prevents the initiation and conduction of nerve impulses. Epinephrine is a sympathomimetic amine that acts as a vasoconstrictor; it is included in the formulation to decrease local blood flow, thereby delaying the systemic absorption of mepivacaine, prolonging its anesthetic effect, and reducing the risk of systemic toxicity. This specific combination (2% mepivacaine with 1:100,000 epinephrine) is frequently used in clinical research, such as studies conducted by the University of Nove de Julho, to evaluate techniques like photobiomodulation for reducing injection-related pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mepivacaine hydrochloride + epinephrine.